Repligen (RGEN) 46th Annual William Blair Growth Stock Conference summary
Event summary combining transcript, slides, and related documents.
46th Annual William Blair Growth Stock Conference summary
3 Jun, 2026Key strategic themes
Innovation and diversification drive growth, with a broad product portfolio and a focus on launching new solutions and technologies across bioprocessing, including fluid management, filtration, chromatography, analytics, proteins, and ligands.
Strategic expansion in Asia, especially China, is a priority, supported by new leadership, OEM deals, and a strategy to capture rapid market growth.
Transformation Office established to accelerate top-line growth and margin improvement, targeting 30% EBITDA margin by 2030 and delivering at least one point of annualized margin benefit by end of 2027.
Digitization and process analytical technologies are central, with plans to integrate digital twins and AI for process optimization.
M&A remains a top capital allocation priority, with recent acquisitions and minority investments supporting growth and innovation.
Financial performance and growth outlook
Achieved $738 million in revenue last year, with FY26 guidance set at $803M–$833M and 9–13% organic growth.
Maintained 16% organic growth last year and 16% organic non-COVID growth in 2025, outpacing industry growth.
Analytics and chromatography franchises projected to grow over 20% in FY26, with analytics up over 50% in Q1.
Targeting mid-teens revenue CAGR through 2030, aiming to double the business primarily via organic growth.
Committed to margin expansion, with a roadmap to ~30% EBITDA margin by 2030, driven by volume leverage, improved mix, and productivity.
Operational initiatives and efficiency
Site rationalization underway, consolidating manufacturing to 8-10 core sites for efficiency and fit-for-growth initiatives.
Service improvements reduced equipment installation time from four months to 1.5 weeks.
Transformation Office also focuses on IT modernization, AI implementation, and operational excellence.
Key account management leverages deep industry relationships to drive sales growth and cross-selling.
Leadership structure strengthened to empower teams and support multi-billion dollar ambitions.
Latest events from Repligen
- Strong Q1, raised guidance, and strategic moves position for sustained growth and margin expansion.RGEN
Bank of America Global Healthcare Conference 202619 May 2026 - Virtual meeting approved all proposals with no shareholder questions or objections.RGEN
AGM 202615 May 2026 - 2026 outlook features robust growth, margin expansion, and strategic investments for long-term scale.RGEN
Leerink Global Healthcare Conference 202613 May 2026 - Q1 2026 delivered 15% revenue growth, margin expansion, and raised FY26 EPS guidance.RGEN
Q1 202611 May 2026 - Board recommends re-electing directors, citing progress on internal controls and diversity.RGEN
Proxy filing27 Apr 2026 - Double-digit growth in FY25 with strong FY26 outlook and margin expansion despite headwinds.RGEN
Q4 202510 Apr 2026 - Proxy covers director elections, auditor ratification, executive pay, and strong 2025 growth.RGEN
Proxy filing2 Apr 2026 - Key votes include board elections, auditor ratification, and executive pay approval.RGEN
Proxy filing2 Apr 2026 - Broad innovation, strong execution, and digital focus drive multi-year growth outlook.RGEN
2026 KeyBanc Capital Markets Healthcare Forum18 Mar 2026